FDA
-
-
-
-
-
-
-
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
-
-
-
-
-
-
-
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
-
-
-
-
-
-
-
Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity
-
-
-
-
-
-
-
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
-
-
-
-
-
-
-
Immunome Reports Second Quarter 2022 Financial Results
-
323,580 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

